Video by Guangming Convergence Media Center
As one of the eight strategic emerging industry clusters in Guangming District, the high-end medical device industry has developed rapidly, with many emerging enterprises such as Dymind Biotechnology Co. Ltd. Recently, the Guangming Convergence Media Center had an interview with Dr. Liu Guangjian, director of the Big Data Center of Dymind Biotechnology, to learn about the future of the high-end medical device industry in Guangming. Join us to explore this emerging scientific research field.
In the following dialogue, "GMCMC" refers to Guangming Convergence Media Center, and "LGJ" refers to Dr. Liu Guangjian.
GMCMC: Could you please introduce us your study and research field?
LGJ: I am Liu Guangjian, a doctor of Biomedical Engineering. As an interdisciplinary research scholar, I have studied a wide range of topics, including basic research, such as molecular modelling, pathological mechanism of diseases, as well as applied research, such as computer-aided drug design and artificial intelligence assisted diagnosis and treatment.
Now I am the Digital Data Director of Dymind. Combining my previous scientific research experience and my deep understanding of the clinical work brought by my hospital work experience, I hope to develop with my colleagues medical devices that are more intelligent and more suitable for clinical use.
GMCMC: How will you apply and develop AI technology in this research field of high-end medical devices?
LGJ: Dymind is a company eager to innovate and brave to innovate, and that constantly creates break-throughs. For medical big data and AI innovation, Dymind can provide a mature technology platform. AI tries to empower high-end medical devices in two directions: one is to reduce repetition work through automation, such as specimen sorting and loading; the other is to empower human beings through intelligent models, enabling them to have higher abilities and do things that previously could not be done. A typical example is the AI image products, which can help doctors find more disease information from the images than human being can alone. In a word, through the combination of these two aspects, AI technologies can make future high-end medical devices more intelligent, personalized and precise.
GMCMC: What are the prospects for the high-end medical device industry in Guangming?
LGJ: Thus far, Dymind has served more than 140 countries and regions in the world. We rank second in the field of hematology analyzers in the domestic market. As an enterprise in Guangming, Dymind has independently launched the world's leading joint inspection machines, promoting new breakthroughs in blood cell analysis equipment.
We hope to participate in the planning and conducting of academic cooperation with more and more excellent scientific research institutions. We hope to solve bottleneck problems through independent research and development efforts, to facilitate the development of domestic substitutions together with other players of the industry, and to build more domestic medical devices to serve all of society.
About Dr. Liu Guangjian
Dr. Liu Guangjian, who holds a Ph.D. degree in Biomedical Engineering, has worked as a medical big data and artificial intelligence scientist at the Guangzhou Women and Children's Medical Center and Guangdong Provincial People's Hospital. He worked as a visiting scholar at the Center for Computational Biology in the University of Birmingham, UK, working with the world's top scientists to explore how to translate the results of basic research and genomics into clinical practice, to develop more effective therapies for cancer and other complex diseases, so that they can better serve patients and benefit human health. Now he is the Digital Data Director of Dymind Biotechnology Co. Ltd.